Feature | January 13, 2010

January 13, 2010 – Research validates the efficacy of the recent reclassification of the T category in the International Association for the Study of Lung Cancer’s (IASLC) "Staging Manual in Thoracic Oncology" released in the January 2010 issue of the Journal of Thoracic Oncology.

In the sixth edition of the tumor, node and metastatis (TNM) staging system, there were no changes. Thus, the change in the seventh edition is significant as it is the first revision of TMN classification in lung cancer for 12 years, and represents the most drastic change there has been in the past 30 years.

The medical records of 1,393 patients with non-small cell lung cancer who underwent complete resection were thoroughly reviewed for pathologic findings and survival. The stage of all the patients was pathologically defined according to the present international staging system, previously revised in 1997. This study examined the relationship between the cut-off points of the tumor size for the new T category and the pathologic invasiveness

The TNM staging system is useful for both the clinical assessment of tumor progression and the determination of treatment plan, such as surgery, chemotherapy and radiation. In the forthcoming TNM classification, a revision with respect to lung cancer has been proposed by the International Association for the Study of Lung Cancer. The major revision is the T category, which makes an especially strict division by detailed cut points of tumor size (e.g., 2-, 3-, 5- and 7-cm). The proposed T revision has been determined and validated based on the overall survival date from a large international database.

The lead study author, Tokujiro Yano, M.D., called the new T classification, which is based mainly on the tumor size, “appropriate for the pathologic findings of the primary tumor.” The significant differences were observed among newly revised T subsets in at least one incidence of pathologic invasiveness, including lymphatic, vascular, or pleural invasion.

Past chair and author of the IASLC’s staging guide, Peter Goldstraw, added that IASLC will play a central role in the formation of future classification of TMN.

For more information: www.iaslcpubs.org/IASLC-Manual-Thoracic-print.html


Related Content

News | FDA

June 4, 2026 — GE HealthCare has received 510(k) clearance from the United States Food and Drug Administration (FDA) for ...

Time June 05, 2026
arrow
News | Radiation Therapy

June 3, 2026 — Alpha Tau Medical Ltd. and Tolmar International Ltd. have announced a strategic collaboration agreement ...

Time June 04, 2026
arrow
News | Radiopharmaceuticals and Tracers

June 1, 2026 — Serac Healthcare Ltd. has presented Phase 2 data showing that SPECT-CT imaging with the radiotracer 99mTc ...

Time June 01, 2026
arrow
News | ASTRO

May 18, 2026 — The American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and ...

Time May 19, 2026
arrow
News | Radiology Imaging

May 18, 2026 — DICO, a company specializing in the creation of distributed diagnostic infrastructure for radiology, has ...

Time May 19, 2026
arrow
News | Women's Health

May 6, 2026 — GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT2, a solution designed to ...

Time May 06, 2026
arrow
News | Radiation Therapy

April 30, 2026 — The Siemens Healthineers business area, Varian, has been awarded up to $60 million over five years by ...

Time April 30, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
Subscribe Now